Tislelizumab and Metronomic Capecitabine as Maintenance in High-risk Locoregionally-advanced Nasopharyngeal Carcinoma

Abroad (travel likely)RecruitingPHASE2

Conditions

Nasopharyngeal Carcinoma

Simple summaryAI-assisted

This summary is produced by a language model and is experimental. It may be incomplete or inaccurate and is not a substitute for professional medical advice.

Locations

National Cancer Centre Singapore, Singapore, Singapore
Tan Tock Seng Hospital, Singapore, Singapore

Study leads

Melvin LK CHUA, MBBS, FRCR, PhD, FAMS, FASCO
Principal Investigator
National Cancer Centre, Singapore

View source on ClinicalTrials.gov

Similar trials

Other trials that are currently recruiting and may be relevant based on condition, treatment, phase, or location

Reduced-dose Radiotherapy for Stage III Nasopharyngeal Carcinoma Based on the Treatment Response

Nasopharyngeal Carcinoma

Abroad (travel likely)RecruitingPHASE3

Fuzhou, China · Xiamen, China

Metronomic Capecitabine With or Without PD-1 Antibody as Adjuvant Therapy in High-risk Nasopharyngeal Carcinoma

Nasopharyngeal Carcinoma

Abroad (travel likely)RecruitingPHASE3

Guangzhou, China

Testing Whether Cemiplimab (REGN2810) Plus CDX-1140 Given Prior to Surgery Are Better Than Cemiplimab (REGN2810) Alone in Patients With Stage III-IV Head and Neck Cancer

Head and Neck Squamous Cell Carcinoma · Hypopharyngeal Squamous Cell Carcinoma · Laryngeal Squamous Cell Carcinoma

Abroad (travel likely)RecruitingPHASE2

Irvine, United States · Orange, United States

CD70-targeted immunoPET Imaging of Malignant Cancers

Renal Cancer · Renal Clear Cell Carcinoma · Lymphoma

Abroad (travel likely)RecruitingPHASE2

Shanghai, China